



(51) International Patent Classification:

A61P 35/00 (2006.01) C07D 413/04 (2006.01)
A61K 31/42 (2006.01) C07D 413/12 (2006.01)
C07D 261/20 (2006.01) C07D 413/14 (2006.01)

(21) International Application Number:

PCT/US2024/060009

(22) International Filing Date:

13 December 2024 (13.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:


63/611,649 18 December 2023 (18.12.2023) US

(71) Applicant: IDEAYA BIOSCIENCES, INC. [US/US];
5000 Shoreline Court, Suite 300, South San Francisco, California 94080 (US).(72) Inventors: JONES, Brian Thomas; 5000 Shoreline Court,
Suite 300, South San Francisco, California 94080 (US).
WANG, Chenbo; 5000 Shoreline Court, Suite 300, South

San Francisco, California 94080 (US). **BARSANTI, Paul A.**; 5000 Shoreline Court, Suite 300, South San Francisco, California 94080 (US). **TAYGERLY, Joshua P.G.**; 5000 Shoreline Court, Suite 300, South San Francisco, California 94080 (US). **SHABALIN, Ivan G.**; 5000 Shoreline Court, Suite 300, South San Francisco, California 94080 (US). **SEVERANCE, Daniel Lee**; 5000 Shoreline Court, Suite 300, South San Francisco, California 94080 (US). **MCCAULEY-WALDEN, Daniel W.**; 5000 Shoreline Court, Suite 300, South San Francisco, California 94080 (US). **RYAN, Jonathon S.**; 5000 Shoreline Court, Suite 300, South San Francisco, California 94080 (US). **KESHIPEDDY, Santosh Kumar**; 5000 Shoreline Court, Suite 300, South San Francisco, California 94080 (US). **ALAM, Muzaffar**; 5000 Shoreline Court, Suite 300, South San Francisco, California 94080 (US). **LI, Jiaming**; 5000 Shoreline Court, Suite 300, South San Francisco, California 94080 (US). **FLEURY, Melissa**; 5000 Shoreline Court, Suite 300, South San Francisco, California 94080 (US). **MATIER, Carson Douglas**; 5000 Shoreline Court, Suite 300, South San Francisco, California 94080 (US). **TAFT,**

(54) Title: CHEMICAL COMPOUNDS AND USES THEREOF

FIG. 1



(57) **Abstract:** Provided herein are compounds of Formula (Y) or a pharmaceutically acceptable salt thereof, wherein L, R^1 , R^{2a} , R^{2b} , R^{3a} , R^{3b} , R^{3c} , R^{3d} , R^4 , R^{5a} , and R^{5b} , have the meanings as provided herein. The provided compounds inhibit KAT6A and/or KAT7 enzyme activity, and are useful in treating cancers treatable by inhibition of KAT6A and/or KAT7. Also, disclosed are pharmaceutical compositions comprising such compounds, methods of using such compounds, and methods of making such compounds.

[Continued on next page]

Benjamin Robert; 5000 Shoreline Court, Suite 300, South San Francisco, California 94080 (US).

(74) **Agent: DOLAN, Gregory F.** et al.; Mintz Levin Cohn Ferris Glovsky and Popeo, PC, One Financial Center, Boston, Massachusetts 02111 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*